Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05722418 · ClinicalTrials.gov registry record · Phase 1

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Caribou Biosciences.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
16
Study locations

NCT05722418: Recruiting Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by Caribou Biosciences.

NCT05722418 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by Caribou Biosciences. The registered enrollment target is 50 participants, below the 169-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (70% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05722418, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Caribou Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

Primary Outcome

Number of patients with DLTs during the 28 days following the first administration of CB-011.

Conditions Studied

Relapsed/Refractory Multiple Myeloma

Interventions

  • BIOLOGICAL CB-011

Study Locations (16)

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Levine Cancer Institute - Charlotte
  • Duke University Health System (DUHS) - Durham

Ohio

  • Oncology Hematology Care, Inc - Cincinnati
  • Cleveland Clinic - Cleveland

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • CU Anschutz Medical Campus, Anshutz Cancer Pavillion - Aurora

Florida

  • Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics - Miami

Kentucky

  • University of Kentucky/ Markey Cancer Center - Lexington

New Jersey

  • Hackensack Meridian John Theurer Cancer Center - Hackensack

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-02-06
Est. Completion 2027-12
Phase Phase 1
Caribou Biosciences

3 total trials

What NCT05722418 shows while recruiting

NCT05722418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 169-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which CB-011 is the first listed.

NCT05722418 lists 16 locations in 13 states (New York, North Carolina, Ohio).

Frequently Asked Questions

What is clinical trial NCT05722418 about?

NCT05722418 is a clinical study titled "CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma". This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma...

What is the current status of trial NCT05722418?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-02-06. Estimated completion is 2027-12.

What conditions does trial NCT05722418 study?

This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.

What interventions are being tested in trial NCT05722418?

The interventions under investigation include: CB-011 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05722418?

This trial is sponsored by Caribou Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05722418 being conducted?

This trial has 16 study locations across Alabama, Colorado, Florida, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed/Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05722418's enrollment target sits among peer trials

50 12th of 14 higher than 3 of 14 other Relapsed/Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05722418

Source: ClinicalTrials.gov NCT05722418, the US trial registry maintained by the National Library of Medicine. NCT05722418 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.